PRAME and cancer: As a dominant repressor, PRAME was involved in the retinoic acid receptor (RAR) signaling in melanoma and other cancer cells [30], though a later study indicated that PRAME was not associated with RAR signaling in primary acute myeloid leukemia [31] and seminomas [32].